Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers.

Bruggmann P.

J Viral Hepat. 2012 Dec;19(12):829-35. doi: 10.1111/jvh.12008. Epub 2012 Oct 1. Review.

PMID:
23205675
2.

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S129-37. doi: 10.1093/cid/cit302.

PMID:
23884061
3.

Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Arain A, Robaeys G.

World J Gastroenterol. 2014 Sep 28;20(36):12722-33. doi: 10.3748/wjg.v20.i36.12722. Review.

4.

Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH.

World J Gastroenterol. 2013 Nov 28;19(44):7846-51. doi: 10.3748/wjg.v19.i44.7846. Review.

5.

Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.

Bruggmann P, Grebely J.

Int J Drug Policy. 2015 Feb;26 Suppl 1:S22-6. doi: 10.1016/j.drugpo.2014.08.014. Epub 2014 Aug 30.

6.

Can hepatitis C virus infection be eradicated in people who inject drugs?

Grebely J, Dore GJ.

Antiviral Res. 2014 Apr;104:62-72. doi: 10.1016/j.antiviral.2014.01.002. Epub 2014 Jan 24. Review.

PMID:
24468275
7.

Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.

Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L.

J Viral Hepat. 2014 Mar;21(3):198-207. doi: 10.1111/jvh.12129. Epub 2013 Jul 1.

PMID:
24438681
8.

Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Bruggmann P, Litwin AH.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S56-61. doi: 10.1093/cid/cit271. Review.

PMID:
23884067
9.

Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.

Department of Veterans Affairs Hepatitis C Resource Center, Yee HS, Currie SL, Darling JM, Wright TL.

Am J Gastroenterol. 2006 Oct;101(10):2360-78.

PMID:
17032203
10.

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

Seeff LB, Hoofnagle JH.

Clin Liver Dis. 2003 Feb;7(1):261-87. Review.

PMID:
12691470
11.

Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients.

Charlebois A, Lee L, Cooper E, Mason K, Powis J.

J Viral Hepat. 2012 Dec;19(12):836-42. doi: 10.1111/j.1365-2893.2012.01648.x. Epub 2012 Jul 31.

PMID:
23121361
12.

HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment.

Walsh N, Maher L.

Curr Opin HIV AIDS. 2012 Jul;7(4):339-44. doi: 10.1097/COH.0b013e328354131e. Review.

PMID:
22498482
13.

Enhancing the detection and management of acute hepatitis C virus infection.

Martinello M, Matthews GV.

Int J Drug Policy. 2015 Oct;26(10):899-910. doi: 10.1016/j.drugpo.2015.07.003. Epub 2015 Jul 16. Review.

PMID:
26254495
14.

The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006.

Gidding HF, Topp L, Middleton M, Robinson K, Hellard M, McCaughan G, Maher L, Kaldor JM, Dore GJ, Law MG.

J Gastroenterol Hepatol. 2009 Oct;24(10):1648-54.

PMID:
19798783
15.

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users.

Int J Drug Policy. 2015 Oct;26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005. Epub 2015 Jul 17.

PMID:
26282715
16.

Advances in the treatment of hepatitis C.

Lawrence SP.

Adv Intern Med. 2000;45:65-105. Review.

PMID:
10635046
17.

Management of HCV and HIV infections among people who inject drugs.

Grebely J, Tyndall MW.

Curr Opin HIV AIDS. 2011 Nov;6(6):501-7. doi: 10.1097/COH.0b013e32834bcb36. Review.

PMID:
22001894
18.

Global policy and access to new hepatitis C therapies for people who inject drugs.

Doyle JS, Aspinall EJ, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME.

Int J Drug Policy. 2015 Nov;26(11):1064-71. doi: 10.1016/j.drugpo.2015.05.008. Epub 2015 Jun 2. Review.

PMID:
26118794
19.

Acute hepatitis C: a systematic review.

Kamal SM.

Am J Gastroenterol. 2008 May;103(5):1283-97; quiz 1298. doi: 10.1111/j.1572-0241.2008.01825.x. Review.

PMID:
18477352
20.

Hepatitis C virus infection in dialysis patients.

Sułowicz W, Radziszewski A, Chowaniec E.

Hemodial Int. 2007 Jul;11(3):286-95. Review.

PMID:
17576291

Supplemental Content

Support Center